PS改良给药与流量CPAP呼吸机治疗新生儿ARDS

PS modified administration and flow CPAP ventilator for the treatment of neonatal ARDS

目的:探讨肺表面活性物质(PS)改良给药与流量持续气道正压通气(CPAP)呼吸机治疗新生儿急性呼吸窘迫综合征(ARDS)的应用效果。方法:选取2020年1月至2022年8月本院收治的72例ARDS新生儿为研究对象,随机分为观察组和对照组,每组36例。对照组为常规治疗+流量CPAP呼吸机治疗,观察组在对照组的基础上联合PS改良给药。比较两组血气分析结果、治疗效果及并发症情况。结果:相较于对照组,观察组肺通气和氧合功能均改善,住院时间、通气时间更短,治疗总有效率更高,并发症发生率更低(P<0.05)。结论:PS改良给药与流量CPAP呼吸机能够改善ARDS患儿的肺通气和氧合功能,促进恢复,减少并发症发生,临床疗效显著。

Objective:To investigate the application effect of pulmonary surfactant(PS)modified drug administration combined with flow continuous positive airway pressure(CPAP)ventilator in neonates with acute respiratory distress syndrome(ARDS).Methods:72 neonates with ARDS admitted to our hospital from January 2020 to August 2022 were selected as subjects,and they were randomly divided into observation group and control group,with 36 cases in each group.The control group was treated with conventional therapy and flow CPAP ventilator,while the observation group was treated with PS modified medication on the basis of the control group.The results of blood gas analysis,therapeutic effect and complications were compared between the two groups.Results:Compared with the control group,the observation group showed improvements in lung ventilation and oxygenation function,shorter hospital stay and ventilation time,higher overall treatment efficiency,and lower incidence of complications(P<0.05).Conclusion:Modified PS administration and flow CPAP ventilator can improve lung ventilation and oxygenation function in children with ARDS,promote recovery,reduce complications,and have significant clinical efficacy.